SCHEMBL7188508

SCHEMBL7188508

Cc1cccc(C)c1C(=O)Pc1ccc(OCC(C)C)cc1OCC(C)C.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 0.41
JUN P05412 2/20 0.41
FFAR1 O14842 2/20 0.39
PPARD Q03181 1/20 0.39
XDH P47989 1/20 0.38
NR1H4 Q96RI1 2/20 0.37
SIRT2 Q8IXJ6 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
PDK2 Q15119 1/20 0.36
TRIM24 O15164 1/20 0.36
MDM2 Q00987 1/20 0.35
MCL1 Q07820 1/20 0.35
KAT6A Q92794 1/20 0.35
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
ATM Q13315 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7188514 0.98 FFAR1 (0.39) FOSJUNFFAR1PPARDXDH
SCHEMBL7181505 0.92 FOS (0.38) FOSJUNFFAR1PPARDXDH
SCHEMBL7182437 0.91 FOS (0.38) FOSJUNFFAR1PPARDXDH
SCHEMBL7175998 0.90 XDH (0.39) FOSJUNFFAR1PPARDXDH
Lithium SCHEMBL7181512 0.90 FOS (0.36) FOSJUNFFAR1PPARDXDH
SCHEMBL7182327 0.88 FOS (0.41) FOSJUNXDHNR1H4SIRT2
Lithium SCHEMBL7182446 0.88 KEAP1 (0.36) FOSJUNFFAR1PPARDXDH
SCHEMBL7177986 0.87 FOS (0.36) FOSJUNFFAR1PPARDXDH
SCHEMBL7187557 0.87 FOS (0.40) FOSJUNXDHNR1H4SIRT2
SCHEMBL7184514 0.87 FOS (0.38) FOSJUNFFAR1PPARDXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FOS 2702/4885JUN 4136/4885FFAR1 671/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FOS 2549/4885JUN 3781/4885FFAR1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.